Inhibrx Biosciences Inc.

14.02
-0.03 (-0.21%)
At close: Apr 02, 2025, 3:59 PM
13.78
-1.71%
Pre-market: Apr 03, 2025, 07:30 AM EDT

Inhibrx Biosciences Statistics

Share Statistics

Inhibrx Biosciences has 14.48M shares outstanding. The number of shares has increased by 0% in one year.

Shares Outstanding 14.48M
Shares Change (YoY) 0%
Shares Change (QoQ) 0%
Owned by Institutions (%) 0.06%
Shares Floating 9.95M
Failed to Deliver (FTD) Shares 99
FTD / Avg. Volume 0.09%

Short Selling Information

The latest short interest is 895.66K, so 6.19% of the outstanding shares have been sold short.

Short Interest 895.66K
Short % of Shares Out 6.19%
Short % of Float 9.01%
Short Ratio (days to cover) 14.06

Valuation Ratios

The PE ratio is 0.14 and the forward PE ratio is -1.82. Inhibrx Biosciences's PEG ratio is 0.

PE Ratio 0.14
Forward PE -1.82
PS Ratio 1139.75
Forward PS 1
PB Ratio 1.71
P/FCF Ratio -1.16
PEG Ratio 0
Financial Ratio History

Enterprise Valuation

Inhibrx Biosciences has an Enterprise Value (EV) of 83.4M.

EV / Sales 417.01
EV / EBITDA 0.05
EV / EBIT -0.43
EV / FCF -0.42

Financial Position

The company has a current ratio of 3.94, with a Debt / Equity ratio of 0.06.

Current Ratio 3.94
Quick Ratio 3.94
Debt / Equity 0.06
Debt / EBITDA 0
Debt / FCF -0.04
Interest Coverage -24.57

Financial Efficiency

Return on Equity is 1263.3% and Return on Invested Capital is -234.02%.

Return on Equity 1263.3%
Return on Assets 933.56%
Return on Invested Capital -234.02%
Revenue Per Employee $1.28K
Profits Per Employee $10.82M
Employee Count 156
Asset Turnover 0
Inventory Turnover n/a

Taxes

Income Tax 2K
Effective Tax Rate 0%

Stock Price Statistics

The stock price has increased by -60.03% in the last 52 weeks. The beta is -1.09, so Inhibrx Biosciences's price volatility has been lower than the market average.

Beta -1.09
52-Week Price Change -60.03%
50-Day Moving Average 13.38
200-Day Moving Average 14.32
Relative Strength Index (RSI) 53.63
Average Volume (20 Days) 110.76K

Income Statement

In the last 12 months, Inhibrx Biosciences had revenue of 200K and earned 1.69B in profits. Earnings per share was 114.01.

Revenue 200K
Gross Profit 200K
Operating Income -331.45M
Net Income 1.69B
EBITDA 1.7B
EBIT 1.7B
Earnings Per Share (EPS) 114.01
Full Income Statement

Balance Sheet

The company has 152.6M in cash and 8.05M in debt, giving a net cash position of 144.55M.

Cash & Cash Equivalents 152.6M
Total Debt 8.05M
Net Cash 144.55M
Retained Earnings -106.13M
Total Assets 180.77M
Working Capital 119.67M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -194.41M and capital expenditures -2.6M, giving a free cash flow of -197.01M.

Operating Cash Flow -194.41M
Capital Expenditures -2.6M
Free Cash Flow -197.01M
FCF Per Share -13.31
Full Cash Flow Statement

Margins

Gross margin is 100%, with operating and profit margins of -165724% and 843786%.

Gross Margin 100%
Operating Margin -165724%
Pretax Margin 843787%
Profit Margin 843786%
EBITDA Margin 851675%
EBIT Margin -165724%
FCF Margin -98503%

Dividends & Yields

INBX does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Payout Ratio n/a
Earnings Yield 740.32%
FCF Yield -86.42%
Dividend Details

Analyst Forecast

Currently there are no analyst rating for INBX.

Price Target n/a
Price Target Difference n/a
Analyst Consensus n/a
Analyst Count n/a
Stock Forecasts

Scores

Altman Z-Score 33.55
Piotroski F-Score 5